S&P 500 Technology Sector SEC Filings — May 19, 2026

19-05-2026

Maui Land & Pineapple Company (MLP) entered a non-binding Memorandum of Understanding (MOU) with the County of Maui to negotiate the sale or lease of certain real property and water infrastructure assets in West Maui and Upcountry Maui. The MOU follows over a year of discussions and includes monetary and non-monetary consideration such as water credits and land use support to facilitate housing development. However, the MOU is non-binding and there is no assurance a definitive agreement will be reached.

• · On September 10, 2025, MLP formed a sub-committee led by Ken Ota to explore strategic sale of water-related assets.
• · The MOU includes conditions that must be satisfied before a definitive agreement.
• · The County of Maui has initiated budget allocations toward the potential purchase.
• · Assets are expected to be valued based on professional appraisals.

19-05-2026

Immunic, Inc. announced the appointment of Michael W. Bonney as Chair of its Board of Directors effective May 16, 2026. Bonney brings over 30 years of biopharmaceutical leadership, including key roles at Biogen (Avonex launch) and as CEO of Cubist Pharmaceuticals. Simona Skerjanec transitions from Interim Chair to board member. The appointment comes ahead of phase 3 ENSURE trial readouts for vidofludimus calcium in relapsing MS, expected by end of 2026.

• · Bonney played key role in launch and growth of Avonex (multiple sclerosis) and led Cubist through acquisition by Merck for ~$9.5B.
• · Phase 3 ENSURE trials for vidofludimus calcium in relapsing MS top-line data expected by end of 2026.
• · Vidofludimus calcium is a Nurr1 activator and DHODH inhibitor with neuroprotective, anti-inflammatory, and anti-viral effects.
• · Immunic also has earlier-stage programs IMU-856 and IMU-381 targeting neurodegenerative and autoimmune diseases.

19-05-2026

Cisco reported strong Q3 FY2026 results with total revenue of $15,841M, up 12.0% YoY from $14,149M, driven by product revenue growth of 16.8% to $12,117M. Net income rose 35.4% to $3,373M ($0.85 per diluted share) from $2,491M ($0.62 per diluted share). However, services revenue declined 1.4% YoY to $3,724M, and operating cash flow decreased 11.7% to $8,791M for the nine-month period, reflecting higher inventory and lower deferred revenue.

• · Gross margin for Q3 FY2026 was $10,080M, up from $9,278M in Q3 FY2025.
• · Total operating expenses for Q3 FY2026 were $6,120M, relatively flat compared to $6,076M in Q3 FY2025.
• · Restructuring and other charges were a credit of $1M in Q3 FY2026 versus a charge of $34M in Q3 FY2025.
• · Interest and other income (loss), net was $79M in Q3 FY2026, compared to a loss of $255M in Q3 FY2025.
• · Provision for income taxes increased to $666M in Q3 FY2026 from $456M in Q3 FY2025.
• · Cash dividends declared were $0.42 per common share in Q3 FY2026, up from $0.41 in Q3 FY2025.
• · Share repurchases totaled $1,252M in Q3 FY2026, compared to $1,504M in Q3 FY2025.
• · Inventories increased to $4,708M at April 25, 2026 from $3,164M at July 26, 2025.
• · Short-term debt rose to $11,932M from $5,232M at July 26, 2025.
• · Long-term debt decreased to $19,371M from $22,861M at July 26, 2025.

19-05-2026

Winnow Wealth LLC filed its Q1 2026 13F-HR, reporting a portfolio of over 123 holdings with total market value of approximately $129.6 million as of March 31, 2026. The largest positions include Innovator ETFs’ defined-outcome and managed-flat strategies, with the top holding being Innovator Equity Managed Flat ETF (242,979 shares) and significant exposure to First Trust Vest target-duration buffer ETFs. The filing is a snapshot of holdings and does not provide period-over-period comparisons, so no performance trends can be assessed.

• · Largest position by shares: Innovator Equity Managed Flat ETF (242,979 shares).
• · Second-largest: Innovator Defined Wealth Shield ETF (136,196 shares).
• · Innovator ETFs Trust is the most represented issuer with 18 distinct holdings.
• · First Trust Vest series collectively account for over 750,000 shares across various target-duration and laddered strategies.
• · Only two fixed-income ETFs appear: iShares 0-3 Month Treasury Bond ETF (108,631 shares) and Simplify Aggregate Bond ETF (25,922 shares).
• · Exposure to a single bitcoin ETP: Calamos Laddered Bitcoin ETF (12,451 shares).
• · No option or convertible securities reported; all entries are common stock or ETF shares.
• · All holdings are reported with sole voting and dispositive power (0 shared/0 none).
• · The filing covers the quarterly period ending March 31, 2026, and was submitted on May 19, 2026.
• · No prior-period comparison data is available in the filing; no quarterly change percentages or market-value deltas are provided.

19-05-2026

XAI Madison Equity Premium Income Fund (MCN) announced that its Board of Trustees, including independent trustees, has unanimously approved the addition of PineBridge Investments, LLC as a second sub-adviser, subject to shareholder approval. If approved, PineBridge will manage a new preferred equity strategy (targeting 20-30% of managed assets), while Madison Asset Management will continue to manage the existing covered call equity strategy (70-80% of assets). The fund's name will change to "XAI Equity Premium Income Fund," and a special shareholder meeting is scheduled for on or about July 30, 2026. The fund's investment objective and management fee (0.80% of average daily managed assets) remain unchanged.

• · The Board of Trustees, including independent trustees, unanimously approved the PineBridge sub-advisory agreement.
• · PineBridge became part of MetLife Investment Management in December 2025.
• · The combined MetLife Investment Management business had $741.7 billion in total AUM as of December 31, 2025.
• · The fund's investment objective remains unchanged: high level of current income and gains, with secondary objective of capital appreciation.
• · The fund's name will change from 'XAI Madison Equity Premium Income Fund' to 'XAI Equity Premium Income Fund'.
• · The special meeting of shareholders is expected on or about July 30, 2026.
• · The proxy statement will be available free of charge at www.sec.gov when filed.
• · Current portfolio managers will continue to manage the covered call equities strategy.
• · The fund's management fee remains 0.80% of average daily managed assets.
• · No financial results or period-over-period comparisons were provided in this filing.

19-05-2026

BlockchAIn Digital Infrastructure, Inc. (AIB) furnished an investor presentation on May 19, 2026, highlighting its power-first AI data center strategy with ~40 MW live and cash-flowing, ~90 MW under development, and a ~395 MW pipeline targeting 2027-2028. The company reported Q1 2026 revenue growth of 9% YoY, operating cash flow tripling, and zero traditional debt, but noted that 25 MW of signed non-binding LOIs are still subject to definitive agreements and that the 395 MW pipeline is at various early stages (due diligence, LOI redline, early engagement).

• · The company has zero traditional debt as of Q1 2026.
• · Operating cash flow tripled in Q1 2026 vs prior year.
• · 79% of total assets are in property, equipment, and goodwill.
• · CLT01 has a firm electricity cost of $0.07/kWh and a PUE of 1.3.
• · The 395 MW pipeline includes DFW01 (20 MW, due diligence, Q4 2026), DFW02 (75 MW, LOI redline, Q3 2027), DFW03 (200 MW, early engagement, Q3 2028), and CLT02 (100 MW, Q2 2028).
• · MSP site (25 MW) is owned and interconnection is in progress, targeting Q4 2026.
• · The company's modular build base-case is 9 months, with 8 key vendors secured for supply chain.
• · Christopher Iannacone was appointed Director of Construction Execution on May 12, 2026, bringing 3+ GW of data center oversight from Amazon.

19-05-2026

AIM ImmunoTech reported a significant increase in stockholder equity from a deficit of approximately $9.8 million as of December 31, 2025, to positive equity of approximately $2.1 million as of March 31, 2026, an improvement of about $11.9 million. The company also extended the maturity date of its promissory note with Streeterville Capital, LLC to June 30, 2027, with an outstanding balance of approximately $1.68 million. While the equity improvement and note extension enhance financial flexibility, the company still has a relatively small equity base and a material debt obligation, and its clinical programs remain subject to significant risks and uncertainties.

• · The promissory note was originally issued on February 16, 2024.
• · The company has raised additional equity-generating funds through various transactions since March 31, 2026.
• · The company's lead product is Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator.
• · The company is focused on the treatment of late-stage pancreatic cancer.

19-05-2026

Acadian Asset Management Inc. filed an 8-K on May 19, 2026, disclosing preliminary assets under management (AUM) of approximately $219 billion as of April 30, 2026, in connection with its Investor Forum. The filing includes a press release and management presentation as exhibits. No period-over-period comparisons or additional financial metrics were provided, limiting the ability to assess performance trends.

• · The filing is under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits).
• · Exhibits include a press release (99.1) and an Investor Forum management presentation (99.2), both dated May 19, 2026.
• · The AUM figure is preliminary and unaudited.

19-05-2026

Bravo Multinational Inc. (BRVO) reported a net loss of $129,175 for Q1 2026, up 81.9% from a $71,019 loss in Q1 2025, driven by a 122% increase in board of director fees to $146,650 and a $28,588 legal settlement expense. Cash and cash equivalents surged to $26,051 from $111 at year-end 2025, while total liabilities rose to $1,210,813 from $1,055,698, and the accumulated deficit widened to $(96,563,824). The company remains in a stockholders' deficit of $(1,184,762).

• · Professional fees decreased 64.9% to $8,892 in Q1 2026 from $25,350 in Q1 2025.
• · General and administrative expenses rose 15.7% to $2,221 from $1,919.
• · Net cash provided by operating activities was $24,190 in Q1 2026 vs. $(25,093) used in Q1 2025.
• · Due to related parties increased to $371,053 from $369,303.
• · Accrued board of directors fees rose to $702,050 from $555,400.
• · No revenue was reported for either period.

19-05-2026

Federal Home Loan Bank of San Francisco filed an 8-K disclosing the issuance of consolidated obligations (bonds and discount notes) on trade dates May 13 and May 15, 2026, with total par value of $50 million. These obligations are joint and several liabilities of the eleven Federal Home Loan Banks and are not guaranteed by the U.S. government. The filing provides details on three specific bond issuances with maturities ranging from 2027 to 2031 and fixed coupon rates between 4.000% and 4.350%.

• · Consolidated obligations are joint and several obligations of all eleven Federal Home Loan Banks and are not guaranteed by the U.S. government.
• · The bonds are callable with European or Bermudan call styles, and all have fixed constant coupon rates.
• · The filing excludes discount notes with maturity of one year or less issued in ordinary course.
• · The Bank may change its method of reporting issuance or assumption of consolidated obligations at any time.

19-05-2026

Analog Devices Inc. (ADI) announced a definitive agreement to acquire Empower Semiconductor, a provider of integrated voltage regulators and power management solutions. The transaction is expected to close in the second half of calendar year 2026, subject to customary closing conditions including HSR antitrust clearance. No financial terms of the acquisition were disclosed in the filing.

• · The acquisition was announced via a joint press release on May 19, 2026 (Exhibit 99.1).
• · Closing is expected in H2 calendar year 2026, pending HSR Act waiting period expiration.
• · The filing is furnished under Item 7.01 (Regulation FD) and is not deemed 'filed' for Section 18 Exchange Act purposes.